Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

primary endpoint by demonstrating superior 24-hour bronchodilation to placeboat 12 weeks measured by trough FEV1 (i.e. forced expiratory volume in one second), a standard measure of lung function[1]. NVA237 was delivered using the Concept1® device, a single-dose dry-powder inhaler.

Key secondary endpoints were improvement in breathlessness assessed using the Transition Dyspnea Index (TDI) at 26 weeks, and improved quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) at 52 weeks. Important secondary endpoints were time to first COPD exacerbation and use of rescue medication during 52 weeks of treatment. The study met all of these endpoints.

The GLOW2 study also showed that NVA237 was well-tolerated with a similar incidence of adverse events for patients treated with NVA237, placebo and open-label tiotropium.

GLOW2 was a 52-week double-blind, placebo-controlled, parallel-group study involving 1,066 patients to assess the efficacy, safety and tolerability of NVA237 in patients with COPD. Patients were randomized into three treatment arms receiving either once-daily NVA237 50 mcg, placebo, or once-daily open-label tiotropium 18 mcg. They were also permitted to use COPD background therapy and rescue medication.

In April 2011 Novartis announced results from the first Phase III clinical trial with NVA237. The pivotal double-blind 26-week GLOW1 study met its primary endpoint by demonstrating superior bronchodilation to placebo at 12 weeks measured by trough FEV1 (p<0.001). The incidence of adverse events was similar in NVA237-treated patients and in those receiving placebo. Further data from GLOW1 will be presented at the European Respiratory Society congress in Amsterdam in September 2011.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura.  Novartis intends to launch NVA237 in 2012 as a once-daily monotherapy for COPD.  The first launch for Q
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ohio, July 30, 2015 Mettler-Toledo International Inc. ... for 2015.  Provided below are the highlights: ... quarter compared with the prior year. Reported sales decreased ... the quarter. , Net earnings per diluted share ... the prior-year period. Adjusted EPS was $2.80 , ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... Nov. 3, 2010 DURECT Corporation (Nasdaq: DRRX ... September 30, 2010. Total revenues were $8.1 million for the ... for the three months ended September 30, 2009; revenues in ... of certain excipients used in REMOXY® to King Pharmaceuticals in ...
... Biotechnology, Inc. (OTC Bulletin Board: CSBR ), a ... tumor specific data to enhance the value of oncology drugs, ... Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as ... 2010. About Champions Biotechnology, Inc. Champions Biotechnology, ...
Cached Medicine Technology:DURECT Corporation Announces Third Quarter 2010 Financial Results 2DURECT Corporation Announces Third Quarter 2010 Financial Results 3DURECT Corporation Announces Third Quarter 2010 Financial Results 4DURECT Corporation Announces Third Quarter 2010 Financial Results 5DURECT Corporation Announces Third Quarter 2010 Financial Results 6DURECT Corporation Announces Third Quarter 2010 Financial Results 7Champions Biotechnology Awarded $1.46 million in Grants 2
(Date:8/1/2015)... ... 2015 , ... AlignLife Office Coordinator Heather Pugh earned the position ... patients at this natural health care center in Winamac. , "Oftentimes patients are in ... role is vital to our approach because we want to focus on the patient ...
(Date:8/1/2015)... ... August 01, 2015 , ... Western University of Health Sciences’ ... comprises a growing percentage of U.S. physicians, and reflects the diversity of the ... of the message delivered by John W. Becher, DO, president of the American ...
(Date:8/1/2015)... ... 2015 , ... The condition where veins are enlarged and gnarled is known ... and discomfort. Those who spend a lot of time on their feet and standing ... doing what it can to create awareness and provide a cure in observance of ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River ... honor by the National Retail Federation, the largest retail trade association in the world, ... Maine business owners to be named as such. According to the NRF’s website, Retail ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional ... portfolio company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 ... state-of-the-art clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional ...
Breaking Medicine News(10 mins):Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... U.S. Food and Drug Administration (FDA) today cleared for ... cancer returning //within five to 10 years after a ... test that profiles genetic activity. ,The MammaPrint ... whether existing cancer will metastasize (spread to other parts ...
... on releasing a new line of digital insulin pens for ... thought //to help patients manage their insulin dosages and avoid ... needle, was unveiled today at Battelle. It is the newest ... Indianapolis-based pharmaceutical company. ,The device, called the ...
... major findings of a new study, children who sleep ... less, and they //are less likely than their counterparts ... this new study were published in the January/February 2007 ... ,Conducted by researchers at Northwestern University, the study looked ...
... three-member medical board, who examined former union coal minister Shibu ... of the Jharkhand Mukti Morcha (JMM) chief to provide him ... ,Considering the swelling in his legs that portends serious heart ... to keep Soren in Dumka, which do not have advanced ...
... developed at Brown University, promises to improve our understanding of ... tomography, or CT, delivers detailed 3-D images, but CT scanners ... that uses X-rays to view objects, can produce moving images ... surgeon trying to figure out the best way to repair ...
... aims to solve the problem of dosage variance and ... for children.//, ,The new Watchhaler product from Activaero ... appeal to kids, with vivid colours and an ‘animal-like ... used in combination with conventional metered dose inhalation devices ...
Cached Medicine News:Health News:FDA Clears Breast Cancer Specific Molecular Prognostic Test 2Health News:FDA Clears Breast Cancer Specific Molecular Prognostic Test 3Health News:Childhood Obesity Linked With Sleep 2Health News:New Inhaler is Child's Play 2Health News:New Inhaler is Child's Play 3
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... of abuse tests are highly accurate in detecting ... cut-off as confirmed by GC/MS testing. This assay ... alternative method (such as GC/MS) must be used ... judgment should be applied to any drug of ...
AccuSign® DOA Series Opiates Test...
... The QuickScreen™ At Home Drug Test is ... the FDA for home use. The kit includes ... easy to read instructions, a handbook with frequently ... ship the sample to the laboratory if the ...
Medicine Products: